This Phase Ib trial is evaluating the safety and effect of giving pembrolizumab (commonly used as an immunotherapy drug), to patients with metastatic non-small cell (NSC) lung cancer, before or after radiotherapy treatment .
This trial is treating patients with non-small cell (NSC) lung cancer.
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiotherapy (SABR) for metastatic NSCLC.
Not Recruiting Hospitals Read More